Your browser doesn't support javascript.
loading
The seroprevalence and trends of SARS-CoV-2 in Delhi, India: A repeated population-based seroepidemiological study
Nandini Sharma; Pragya Sharma; Saurav Basu; Sonal Saxena; Rohit Chawla; Kumar Dushyant; Nutan Mundeja; Z SK Marak; Sanjay Singh; Gautam Kumar Singh; Ruchir Rustagi.
Afiliação
  • Nandini Sharma; Maulana Azad Medical College, New Delhi
  • Pragya Sharma; Maulana Azad Medical College, New Delhi
  • Saurav Basu; Maulana Azad Medical College, New Delhi
  • Sonal Saxena; Maulana Azad Medical College, New Delhi
  • Rohit Chawla; Maulana Azad Medical College, New Delhi
  • Kumar Dushyant; Maulana Azad Medical College, New Delhi
  • Nutan Mundeja; Directorate General Health Services, Government of National Capital Territory, Delhi
  • Z SK Marak; Directorate General Health Services, Government of National Capital Territory, Delhi
  • Sanjay Singh; State Surveillance Unit, Public Health Wing-IV, Directorate General Health Services, Government of National Capital Territory, Delhi
  • Gautam Kumar Singh; Directorate General Health Services, Government of National Capital Territory, Delhi
  • Ruchir Rustagi; State Surveillance Unit, Public Health Wing-IV, Directorate General Health Services, Government of National Capital Territory, Delhi
Preprint em En | PREPRINT-MEDRXIV | ID: ppmedrxiv-20248123
ABSTRACT
BackgroundThree rounds of a repeated cross-sectional serosurvey to estimate the seroprevalence and trends of SARS-CoV-2 were conducted from August-October 2020 in the state of Delhi in India in the general population aged [≥]5 years. MethodsThe selection of participants was through a multi-stage sampling design from all the 11 districts and 280 wards of the city-state, with two-stage allocation proportional to population- size. Household selected was via systematic random sampling, and individual participant selection through the age-order procedure. The blood samples were screened using the IgG ELISA COVID-Kawach kit (August Round), and the ERBALISA COVID-19 IgG (September and October) rounds. The seroprevalence was estimated by applying the sampling weights based on age and sex with further adjustment for the assay-kit characteristics. ResultsA total of 4267 (n=15046), 4311 (n=17409), and 3829 (n=15015) positive tests indicative of the presence of IgG antibody to SARS-CoV-2 were observed during the August, September, and October 2020 serosurvey rounds, respectively. The adjusted seroprevalence declined from 28.39% (95% CI 27.65-29.14) (August) to 24.08% (95% CI 23.43-24.74) (September), and 24.71% (95% CI 24.01, 25.42%) (October). The antibody positivity was highest in the [≥]50 and female age-group during all rounds of the serosurvey, while the decline was maximum among the younger age-group (5-17 years). On adjusted analysis, participants with lower per capita income, living in slums or overcrowded households, and those with diabetes comorbidity had significantly higher statistical odds of antibody positivity. ConclusionsDespite high IgG seroprevalence, there was evidence for waning of antibody positivity with the progression of the COVID-19 epidemic, implying a potential reduction in population immunity, especially if also associated with the lack of trained T cell immunity.
Licença
cc_by_nc_nd
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Observational_studies / Prognostic_studies / Rct / Systematic_reviews Idioma: En Ano de publicação: 2020 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Observational_studies / Prognostic_studies / Rct / Systematic_reviews Idioma: En Ano de publicação: 2020 Tipo de documento: Preprint